19645f04-0021-4b2d-ad56-b1342c6ca519
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- UV_RESPONSE_DN+0.260
- SPERMATOGENESIS+0.220
- KRAS_SIGNALING_UP+0.200
- MITOTIC_SPINDLE+0.180
- INFLAMMATORY_RESPONSE+0.140
- ANGIOGENESIS+0.110
- ANDROGEN_RESPONSE+0.100
- MYOGENESIS+0.090
- ALLOGRAFT_REJECTION+0.080
Top 10 suppressed
- MYC_TARGETS_V2-0.410
- PANCREAS_BETA_CELLS-0.380
- DNA_REPAIR-0.360
- P53_PATHWAY-0.360
- APICAL_SURFACE-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.340
- UV_RESPONSE_UP-0.340
- XENOBIOTIC_METABOLISM-0.320
- OXIDATIVE_PHOSPHORYLATION-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c874c481-cff8-4e2d-99b1-3b5aeaaecb8e | — | — | 0.873 |
| 2 | ba2b0b86-f7f1-47f7-b0fd-bec3f623febb | — | — | 0.863 |
| 3 | TCGA-44-2665-01B-06R-A277-07 | — | cohortMD2 | 0.796 |
| 4 | 5abd486a-6aed-4dcf-a2a2-2537af6cdd9c | — | — | 0.793 |
| 5 | TCGA-22-1016-01A-01R-A96U-41 | — | cohortMD2 | 0.792 |
| 6 | TCGA-A7-A13E-01B-06R-A277-07 | — | D | 0.788 |
| 7 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.787 |
| 8 | cd10f4f7-d92b-4152-8595-332686e4605a | — | — | 0.784 |
| 9 | ec48e2b8-ca0a-40fe-a87b-f0e955466840 | — | — | 0.779 |
| 10 | d1447a31-64bb-4e70-ae50-eeff7a605f38 | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |